NDAINTRAVENOUSPOWDERPriority Review
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
EMBLAVEO (aztreonam and avibactam) by AbbVie is beta lactamase inhibitors [moa]. Approved for older, no alternative options for the treatment of complicated intra-abdominal infections (ciai) including those caused by the following susceptible gram-negative microorganisms: escherichia coli, klebsiella pneumoniae and 4 more indications. First approved in 2025.
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMBLAVEO is an intravenous combination of aztreonam and avibactam, a beta-lactamase inhibitor designed to restore the activity of aztreonam against resistant gram-negative bacteria. It is indicated for complicated intra-abdominal infections (cIAI) caused by susceptible gram-negative organisms when no alternative options exist. The avibactam component inhibits beta-lactamases that would otherwise degrade aztreonam, providing coverage against resistant pathogens.
Growth5.9 years to LOE
Recently approved product in growth phase offers early-career opportunity with emerging market potential but limited commercial data; team size likely expanding.
Mechanism of Action
beta Lactamase Inhibitors
Pharmacologic Class:
beta Lactamase Inhibitor
Worked on EMBLAVEO at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.